From Axovant's prospectus:"Weintend to use the net proceeds (40...

Originallypostedbylawrence1967

https://www.sec.gov/Archives/edgar/data/1636050/000104746919001193/a2238033z424b5.htm
TheAXO-AAV-OPMDclinicalprogramisexpectedtobegininthesecondhalfof2019,andthefinaldesignwillbeinformedbydiscussionswiththeFDAandotherregulators.

fromtheAxovantprospectus:

	GeneTherapyProgram		ClinicalIndication		DevelopmentStage
1	AXO-AAV-GM1		GM1gangliosidosis		Clinical-ready
2	AXO-AAV-GM2		GM2gangliosidosis(includingTay-SachsdiseaseandSandhoffdisease)		Clinical
3	AXO-LENTI-PD		Parkinson'sdisease		Clinical
4	AXO-AAV-OPMD		Oculopharyngealmusculardystrophy		Preclinical
5	AXO-AAV-ALS		Amyotrophiclateralsclerosis		Research
6	AXO-AAV-FTD		Frontotemporaldementia		Research
7	FouradditionalAXO-AAV		Undisclosed		Research
8	CollaborationPrograms

From Axovant's prospectus:

"Weintend to use the net proceeds (40 million) from this offering to advance the development of AXO-LENTI-PD, AXO-AAV-GM1, AXO-AAV-GM2 and AXO-AAV-OPMD, as well as additional business development activities. Theremaining proceeds, if any, will be used for working capital and other general corporate purposes, including the payment of milestones under our license agreements as they become due."